Is DNLI or ANNX more profitable?

Denali Therapeutics' return on equity of -55.27% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Annexon N/A -106.15% -79.82%

Does the media prefer DNLI or ANNX?

In the previous week, Annexon had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Annexon's score of 0.89 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ANNX or VCYT?

Veracyte has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Veracyte $517.15M 6.35 $66.35M $1.41 28.99

Is ANNX or VCYT more profitable?

Veracyte has a net margin of 20.37% compared to Annexon's net margin of 0.00%. Veracyte's return on equity of 9.26% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Veracyte 20.37% 9.26% 8.61%

Does the media refer more to ANNX or VCYT?

In the previous week, Veracyte had 1 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Veracyte and 5 mentions for Annexon. Annexon's average media sentiment score of 0.89 beat Veracyte's score of 0.44 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GRAL or ANNX?

Annexon has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is GRAL or ANNX more profitable?

Annexon has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Annexon N/A -106.15% -79.82%

Does the media refer more to GRAL or ANNX?

In the previous week, GRAIL had 4 more articles in the media than Annexon. MarketBeat recorded 9 mentions for GRAIL and 5 mentions for Annexon. GRAIL's average media sentiment score of 0.96 beat Annexon's score of 0.89 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or IDYA more profitable?

Annexon has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% IDEAYA Biosciences -75.93% -16.73% -15.34%

Does the media favor ANNX or IDYA?

In the previous week, IDEAYA Biosciences had 8 more articles in the media than Annexon. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 5 mentions for Annexon. Annexon's average media sentiment score of 0.89 beat IDEAYA Biosciences' score of 0.64 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANNX or ABCL?

In the previous week, Annexon had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Annexon and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat Annexon's score of 0.89 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annexon (ANNX) Competitors

$3.94 -0.20 (-4.83%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.00 +0.06 (+1.50%)

As of 09/11/2026 07:39 PM Eastern

Compare

ANNX vs. DNLI, VCYT, GRAL, IDYA, and ABCL

Should you buy Annexon stock or one of its competitors? Annexon's main competitors and comparable companies include Denali Therapeutics (DNLI), Veracyte (VCYT), GRAIL (GRAL), IDEAYA Biosciences (IDYA), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annexon compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Annexon has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

In the previous week, Annexon had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Annexon's score of 0.89 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics currently has a consensus target price of $35.85, suggesting a potential upside of 69.97%. Annexon has a consensus target price of $15.14, suggesting a potential upside of 284.34%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Denali Therapeutics' return on equity of -55.27% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Annexon	N/A	-106.15%	-79.82%

92.9% of Denali Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics and Annexon tied by winning 7 of the 14 factors compared between the two stocks.

How does Annexon compare to Veracyte?

Annexon (NASDAQ:ANNX) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Annexon currently has a consensus target price of $15.14, indicating a potential upside of 284.34%. Veracyte has a consensus target price of $55.78, indicating a potential upside of 36.48%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91

Annexon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

In the previous week, Veracyte had 1 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Veracyte and 5 mentions for Annexon. Annexon's average media sentiment score of 0.89 beat Veracyte's score of 0.44 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99

Veracyte has a net margin of 20.37% compared to Annexon's net margin of 0.00%. Veracyte's return on equity of 9.26% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats Annexon on 11 of the 14 factors compared between the two stocks.

How does Annexon compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

GRAIL has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

GRAIL presently has a consensus price target of $71.11, indicating a potential downside of 6.72%. Annexon has a consensus price target of $15.14, indicating a potential upside of 284.34%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, GRAIL had 4 more articles in the media than Annexon. MarketBeat recorded 9 mentions for GRAIL and 5 mentions for Annexon. GRAIL's average media sentiment score of 0.96 beat Annexon's score of 0.89 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Annexon	N/A	-106.15%	-79.82%

Annexon has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Summary

GRAIL beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Annexon compare to IDEAYA Biosciences?

Annexon (NASDAQ:ANNX) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Annexon currently has a consensus price target of $15.14, indicating a potential upside of 284.34%. IDEAYA Biosciences has a consensus price target of $52.69, indicating a potential upside of 40.18%. Given Annexon's higher probable upside, equities research analysts clearly believe Annexon is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

IDEAYA Biosciences has higher revenue and earnings than Annexon. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
IDEAYA Biosciences	$218.71M	15.10	-$113.70M	-$1.94	N/A

In the previous week, IDEAYA Biosciences had 8 more articles in the media than Annexon. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 5 mentions for Annexon. Annexon's average media sentiment score of 0.89 beat IDEAYA Biosciences' score of 0.64 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Annexon has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Summary

IDEAYA Biosciences beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Annexon compare to AbCellera Biologics?

Annexon (NASDAQ:ANNX) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Annexon had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Annexon and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat Annexon's score of 0.89 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

61.4% of AbCellera Biologics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AbCellera Biologics has higher revenue and earnings than Annexon. AbCellera Biologics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
AbCellera Biologics	$66.17M	50.46	-$146.41M	-$0.54	N/A

Annexon has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Annexon presently has a consensus price target of $15.14, suggesting a potential upside of 284.34%. AbCellera Biologics has a consensus price target of $12.83, suggesting a potential upside of 17.85%. Given Annexon's higher probable upside, equities analysts plainly believe Annexon is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Annexon on 11 of the 16 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$784.86M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-3.40	14.25	275.24	25.29
Price / Sales	N/A	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	2.77	15.12	10.33	6.20
Net Income	-$206.69M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-19.10%	-4.34%	-3.32%	-2.35%
1 Month Performance	-26.08%	-0.02%	-0.41%	-2.77%
1 Year Performance	62.81%	40.64%	19.21%	7.63%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	2.4103 of 5 stars	$3.94 -4.8%	$15.14 +284.3%	+54.5%	$784.86M	N/A	N/A	60
DNLI Denali Therapeutics	3.7567 of 5 stars	$22.80 -0.2%	$35.85 +57.2%	+42.3%	$3.65B	$330.53M	N/A	430	Positive News
VCYT Veracyte	4.3682 of 5 stars	$44.67 -0.5%	$54.33 +21.6%	+28.3%	$3.61B	$517.15M	31.68	790	Analyst Upgrade
GRAL GRAIL	0.6883 of 5 stars	$80.62 +0.1%	$67.78 -15.9%	+97.2%	$3.60B	$147.17M	N/A	1,360	Analyst Upgrade
IDYA IDEAYA Biosciences	3.1081 of 5 stars	$39.97 -0.5%	$50.19 +25.6%	+50.8%	$3.53B	$218.71M	N/A	80	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. DNLI, VCYT, GRAL, IDYA, and ABCL

How does Annexon compare to Denali Therapeutics?

Summary

How does Annexon compare to Veracyte?

Summary

How does Annexon compare to GRAIL?

Summary

How does Annexon compare to IDEAYA Biosciences?

Summary

How does Annexon compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. DNLI, VCYT, GRAL, IDYA, and ABCL

How does Annexon compare to Denali Therapeutics?

Which has preferable earnings and valuation, DNLI or ANNX?

Which has more volatility and risk, DNLI or ANNX?

Does the media prefer DNLI or ANNX?

Do analysts prefer DNLI or ANNX?

Is DNLI or ANNX more profitable?

Do insiders and institutionals hold more shares of DNLI or ANNX?

Summary

How does Annexon compare to Veracyte?

Do analysts prefer ANNX or VCYT?

Which has more risk & volatility, ANNX or VCYT?

Does the media refer more to ANNX or VCYT?

Which has preferable valuation and earnings, ANNX or VCYT?

Is ANNX or VCYT more profitable?

Summary

How does Annexon compare to GRAIL?

Which has more risk and volatility, GRAL or ANNX?

Do analysts recommend GRAL or ANNX?

Does the media refer more to GRAL or ANNX?

Is GRAL or ANNX more profitable?

Which has better valuation & earnings, GRAL or ANNX?

Summary

How does Annexon compare to IDEAYA Biosciences?

Do analysts rate ANNX or IDYA?

Which has preferable earnings & valuation, ANNX or IDYA?

Does the media favor ANNX or IDYA?

Which has more risk & volatility, ANNX or IDYA?

Do insiders & institutionals have more ownership in ANNX or IDYA?

Is ANNX or IDYA more profitable?

Summary

How does Annexon compare to AbCellera Biologics?

Does the media favor ANNX or ABCL?

Which has more volatility & risk, ANNX or ABCL?

Do institutionals and insiders have more ownership in ANNX or ABCL?

Which has stronger valuation and earnings, ANNX or ABCL?

Is ANNX or ABCL more profitable?

Do analysts rate ANNX or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools